---

Insights on C-peptide in diabetes

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Anuj Maheshwari*

Volume : 6, Issue : 2, Year : 2023

Article Page : 63-65

https://doi.org/10.18231/j.ijnmhs.2023.009

Suggest article by email

Get Permission

Abstract

C-peptide, a key biomarker for beta-cell function in diabetes, has potential in understanding and managing the disease, though its application in type 2 diabetes is limited by insufficient evidence. It provides insights into endogenous insulin secretion and faces challenges in measurement standardization. In type 1 diabetes, C-peptide levels reflect beta cell loss, while in type 2 diabetes, higher levels indicate a higher risk of progression. Preserved C-peptide levels differentiate maturity onset diabetes of the young (MODY) from type 1 diabetes. C-peptide is also associated with gestational diabetes risk. It shows correlations with improved outcomes in type 1 diabetes but controversial associations with macrovascular complications. Despite its promise, standardization, interpretation, and utilization issues require further research and trials for personalized treatments in diabetes.

Keywords: C-Peptide, Beta cells, Type 1 DM, Type 2 DM, MODY, GDM

How to cite : Maheshwari A, Insights on C-peptide in diabetes. J Nutr Metab Health Sci 2023;6(2):63-65

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.